Itovebi

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

News

Celcuity eyes big market opportunity after breast cancer win

Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.

News

Autolus closes on EU okay for leukaemia cell therapy

The CHMP backed approval of Autolus' leukaemia CAR-T Aucatzyl, as well as drugs from GSK, Roche, SpringWorks, and others, at its May meeting.

News

ASCO 25: Roche places Itovebi marker in breast cancer

Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.

News

Roche gets FDA green light for breast cancer drug Itovebi

The FDA has given Roche its first regulatory approval for PI3K inhibitor Itovebi, clearing the drug as part of a triple therapy for certain types of locally advanced or metastatic breast ca

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Celcuity eyes big market opportunity after breast cancer win

Autolus closes on EU okay for leukaemia cell therapy

ASCO 25: Roche places Itovebi marker in breast cancer

Roche gets FDA green light for breast cancer drug Itovebi

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Itovebi

Editor's Picks